| Literature DB >> 27913437 |
Alessandra Metelli1, Bill X Wu1, Caroline W Fugle1, Saleh Rachidi1, Shaoli Sun2, Yongliang Zhang1, Jennifer Wu1, Stephen Tomlinson1, Philip H Howe3, Yi Yang1, Elizabeth Garrett-Mayer4, Bei Liu1, Zihai Li5.
Abstract
GARP encoded by the Lrrc32 gene is the cell surface docking receptor for latent TGFβ, which is expressed naturally by platelets and regulatory T cells (Treg). Although Lrrc32 is amplified frequently in breast cancer, the expression and relevant functions of GARP in cancer have not been explored. Here, we report that GARP exerts oncogenic effects, promoting immune tolerance by enriching and activating latent TGFβ in the tumor microenvironment. We found that human breast, lung, and colon cancers expressed GARP aberrantly. In genetic studies in normal mammary gland epithelial and carcinoma cells, GARP expression increased TGFβ bioactivity and promoted malignant transformation in immunodeficient mice. In breast carcinoma-bearing mice that were immunocompetent, GARP overexpression promoted Foxp3+ Treg activity, which in turn contributed to enhancing cancer progression and metastasis. Notably, administration of a GARP-specific mAb limited metastasis in an orthotopic model of human breast cancer. Overall, these results define the oncogenic effects of the GARP-TGFβ axis in the tumor microenvironment and suggest mechanisms that might be exploited for diagnostic and therapeutic purposes. Cancer Res; 76(24); 7106-17. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27913437 PMCID: PMC5504525 DOI: 10.1158/0008-5472.CAN-16-1456
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701